Heptares signs deal with Takeda for single CNS GPCR target
This article was originally published in Scrip
Executive Summary
UK biotech company Heptares Therapeutics has entered a two-year drug discovery collaboration with Takeda Pharmaceutical. The deal focuses on an undisclosed single G-protein coupled receptor (GPCR) involved in central nervous system (CNS) disorders.